Patents by Inventor Yu-Chi Yang

Yu-Chi Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240100056
    Abstract: The present disclosure relates to methods for the treatment of diseases or disorders (e.g., cancer) with mTOR inhibitors. Specifically, the disclosure relates to methods of treating a subject having a cancer by administering a particular dosage of an mTOR inhibitor. In some embodiments this disclosure includes methods for delaying, preventing, or treating acquired resistance to RAS inhibitors using a dosage of an mTOR inhibitor. In some embodiments, this disclosure relates to methods of treating or preventing adverse events associated with administration of an mTOR inhibitor using tacrolimus.
    Type: Application
    Filed: November 9, 2023
    Publication date: March 28, 2024
    Inventors: Bojena BITMAN, W. Clay GUSTAFSON, Ed LORENZANA, Justin G. MEYEROWITZ, Yu Chi YANG, Mallika SINGH, Zhengping WANG, Zhican WANG
  • Publication number: 20240082249
    Abstract: The present disclosure relates to methods for the treatment of diseases or disorders (e.g., cancer) with mTOR inhibitors. Specifically, the disclosure relates to methods of treating a subject having a cancer by administering a particular dosage of an mTOR inhibitor. In some embodiments this disclosure includes methods for delaying, preventing, or treating acquired resistance to RAS inhibitors using a dosage of an mTOR inhibitor. In some embodiments, this disclosure relates to methods of treating or preventing adverse events associated with administration of an mTOR inhibitor using tacrolimus.
    Type: Application
    Filed: May 25, 2023
    Publication date: March 14, 2024
    Inventors: Bojena BITMAN, W. Clay GUSTAFSON, Ed LORENZANA, Justin G. MEYEROWITZ, Yu Chi YANG, Mallika SINGH, Zhengping WANG, Zhican WANG
  • Patent number: 11919874
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Grant
    Filed: August 17, 2021
    Date of Patent: March 5, 2024
    Assignees: The University of British Columbia, Provincial Health Services Authority
    Inventors: Raymond J. Andersen, Marianne Dorothy Sadar, Kunzhong Jian, Nasrin R. Mawji, Jun Wang, Carmen Adriana Banuelos, Yu-Chi Yang
  • Publication number: 20230233569
    Abstract: The present disclosure relates to compositions and methods for the treatment of diseases or disorders (e.g., cancer) with bi-steric inhibitors of mTOR in combination with RAS inhibitors. Specifically, in some embodiments this disclosure includes compositions and methods for inducing apoptosis of tumor cells and/or for delaying, preventing, or treating acquired resistance to RAS inhibitors using bi-steric mTOR inhibitors.
    Type: Application
    Filed: June 21, 2021
    Publication date: July 27, 2023
    Inventors: Mallika SINGH, Jingjing JIANG, Yu Chi YANG, James W. EVANS, Christopher J. SCHULZE
  • Publication number: 20220378213
    Abstract: A multifunctional sofa includes a base seat, a back supporting frame and a cushion pad. The base seat includes a frame, a support cloth located inside the frame, and a plurality of resilient members connected between the frame and the support cloth. The back supporting frame is disposed at a side of the frame of the base seat. The cushion pad is disposed on the base seat. At a lifted-up posture, the multifunctional sofa serves as a chair. At a lay-down posture, the multifunctional sofa serves as a bed. When the cushion pad is removed, the multifunctional sofa serves as a trampoline on which the user may practice jumping exercise. In accordance with the user's requirement, the multifunctional sofa can be utilized as a chair for sitting, a bed for lying, or a trampoline for jumping so as to preserve more space for home activities.
    Type: Application
    Filed: June 30, 2021
    Publication date: December 1, 2022
    Inventors: Chuan-Hang SHIH, Yu-Chi YANG, Syuan-Yu CHEN
  • Publication number: 20210393042
    Abstract: An electric bed capable of being assembled and dismantled without the need of using a tool is disclosed. The electric bed includes left and right modules, front and rear transverse beams having two ends bare-handed detachably mounted with the left and right modules respectively, and back, buttock, thigh and lower leg supporting units bare-handed detachably mounted with the left and right modules, respectively. A front actuator has two ends bare-handed detachably and pivotally connected with the front transverse beam and the back supporting unit, respectively. A rear actuator has two ends bare-handed detachably and pivotally connected with the rear transverse beam and the thigh supporting unit, respectively. As such, the electric bed can be easily and conveniently assembled and dismantled in accordance with the user's requirement and can be packed with minimized volume of packing material to reduce the transportation cost.
    Type: Application
    Filed: June 17, 2021
    Publication date: December 23, 2021
    Inventors: Chuan-Hang SHIH, Yu-Chi YANG
  • Publication number: 20210387957
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Application
    Filed: August 17, 2021
    Publication date: December 16, 2021
    Inventors: Raymond J. Andersen, Marianne Dorothy Sadar, Kunzhong Jian, Nasrin R. Mawji, Jun Wang, Carmen Adriana Banuelos, Yu-Chi Yang
  • Patent number: 11142508
    Abstract: Compounds having a structure of Formula I or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: October 12, 2021
    Assignees: The University of British Columbia, Provincial Health Services Authority
    Inventors: Raymond J. Andersen, Marianne Dorothy Sadar, Kunzhong Jian, Nasrin R. Mawji, Jun Wang, Carmen Adriana Banuelos, Yu-Chi Yang
  • Publication number: 20200317628
    Abstract: Compounds having a structure of Formula I or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Application
    Filed: April 14, 2020
    Publication date: October 8, 2020
    Inventors: Raymond J. Andersen, Marianne Dorothy Sadar, Kunzhong Jian, Nasrin R. Mawji, Jun Wang, Carmen Adriana Banuelos, Yu-Chi Yang
  • Publication number: 20170298033
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Application
    Filed: April 17, 2017
    Publication date: October 19, 2017
    Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, British Columbia Cancer Agency Branch
    Inventors: Raymond ANDERSEN, Marianne Dorothy SADAR, Kunzhong JIAN, Nasrin R. MAWJI, Jun WANG, Carmen Adriana BANUELOS, Yu-Chi YANG
  • Patent number: 8673312
    Abstract: Helicobacter pylori is closely associated with chronic gastritis, peptic ulcer disease, and gastric adenocarcinoma. Helicobacter pylori neutrophil-activating protein (HP-NAP), a virulence factor of Helicobacter pylori, plays an important role in pathogenesis of Helicobacter pylori infection. Since HP-NAP has been proposed as a candidate vaccine against Helicobacter pylori infection, an efficient way to obtain pure HP-NAP needs to be developed. In the present invention, recombinant HP-NAP expressed in Bacillus subtilis and Escherichia coli was purified through a single step of DEAE SEPHADEX ion-exchange chromatography with high purity. Also, purified recombinant HP-NAP was able to stimulate neutrophils to produce reactive oxygen species. Thus, recombinant HP-NAP obtained from our Bacillus subtilis expression system and Escherichia coli expression system is functionally active.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: March 18, 2014
    Assignee: National Tsing Hua University
    Inventors: Hua-Wen Fu, Kuo-Shun Shih, Chih-Chang Lin, Yu-Chi Yang
  • Publication number: 20130190482
    Abstract: Helicobacter pylori is closely associated with chronic gastritis, peptic ulcer disease, and gastric adenocarcinoma. Helicobacter pylori neutrophil-activating protein (HP-NAP), a virulence factor of Helicobacter pylori, plays an important role in pathogenesis of Helicobacter pylori infection. Since HP-NAP has been proposed as a candidate vaccine against Helicobacter pylori infection, an efficient way to obtain pure HP-NAP needs to be developed. In the present invention, recombinant HP-NAP expressed in Bacillus subtilis and Escherichia coli was purified through a single step of DEAE Sephadex ion-exchange chromatography with high purity. Also, purified recombinant HP-NAP was able to stimulate neutrophils to produce reactive oxygen species. Thus, recombinant HP-NAP obtained from our Bacillus subtilis expression system and Escherichia coli expression system is functionally active.
    Type: Application
    Filed: July 27, 2012
    Publication date: July 25, 2013
    Applicant: NATIONAL TSING HUA UNIVERSITY
    Inventors: Hua-Wen Fu, Kuo-Shun Shih, Chih-Chang Lin, Yu-Chi Yang
  • Patent number: 7425736
    Abstract: A silicon layer with high resistance is provided. The silicon layer with high resistance is positioned on a substrate. Also, the silicon layer with high resistance includes a plurality of silicon material layers, and an interface layer between every two of the silicon material layers, wherein, the silicon material layers and the interface layer have dopants therein. The amount of implanted dopants is about 1*1014˜5*1015 ions/cm2, and the silicon material layers have different grain boundaries.
    Type: Grant
    Filed: June 7, 2005
    Date of Patent: September 16, 2008
    Assignee: United Microelectronics Corp.
    Inventor: Yu-Chi Yang
  • Publication number: 20080050896
    Abstract: A silicon layer with high resistance is provided. The silicon layer with high resistance is positioned on a substrate. Also, the silicon layer with high resistance includes a plurality of silicon material layers, and an interface layer between every two of the silicon material layers, wherein, the silicon material layers and the interface layer have dopants therein. The amount of implanted dopants is about 1*1014˜5*1015 ions/cm2, and the silicon material layers have different grain boundaries.
    Type: Application
    Filed: October 31, 2007
    Publication date: February 28, 2008
    Applicant: UNITED MICROELECTRONICS CORP.
    Inventor: Yu-Chi Yang
  • Publication number: 20060273322
    Abstract: A silicon layer with high resistance is provided. The silicon layer with high resistance is positioned on a substrate. Also, the silicon layer with high resistance includes a plurality of silicon material layers, and an interface layer between every two of the silicon material layers, wherein, the silicon material layers and the interface layer have dopants therein. The amount of implanted dopants is about 1*1014˜5*1015 ions/cm2, and the silicon material layers have different grain boundaries.
    Type: Application
    Filed: June 7, 2005
    Publication date: December 7, 2006
    Inventor: Yu-Chi Yang